Ovarian cancer: add-on BVZ boosts PFS regardless of residual disease

  • González Martín A & al.
  • Gynecol Oncol
  • 15 Nov 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding bevacizumab (BVZ) to front-line chemotherapy improved PFS in patients with stage III-IV ovarian cancer irrespective of residual disease.
  • BVZ improved OS in high-risk patients.

Why this matters

  • Findings suggest add-on BVZ can further improve PFS in patients with residual disease after complete resection.

Study design

  • In phase 3 ICON7 trial, 1528 patients with stage IIB-IV or high-risk stage I-IIA ovarian cancer were randomly assigned to receive 6 cycles of carboplatin+paclitaxel either alone or with BVZ, followed by 12 cycles of BVZ alone.
  • Funding: F. Hoffmann-La Roche Ltd.

Key results

  • Median duration of follow-up was 28 months for PFS and 49 months for OS.
  • Add-on BVZ improved PFS in subgroups:
    • Stage III: HR, 0.85; 95% CI, 0.73-0.99.
    • Stage IV: HR, 0.70; 95% CI, 0.52-0.95.
    • Stage IIIB-IV with no visible disease: HR, 0.77; 95% CI, 0.59-0.99.
    • Stage IIIB-IV and visible residuum HR, 0.81; 95% CI, 0.69-0.95.
  • No PFS benefit was seen with BVZ in stage I/II disease.
  • BVZ significantly improved OS in high-risk patients (HR, 0.78; 95% CI, 0.63-0.97), but not in intent-to-treat population or other subgroups.
  • Safety results in analyzed subgroups were consistent with the overall population.

Limitations

  • Post hoc analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit